Stock Research: Dexcom

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Dexcom

NasdaqGS:DXCM US2521311074
67
  • Value
    43
  • Growth
    68
  • Safety
    Safety
    10
  • Combined
    23
  • Sentiment
    94
  • 360° View
    360° View
    67
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

DexCom, Inc. is a medical device company focused on continuous glucose monitoring systems. The company operates in the medical device industry and its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The company enables people to take control of health through innovative biosensing technology. In the last fiscal year, the company had a market cap of $33,519 million, profits of $2,492 million, revenue of $4,033 million, and 10300 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 67 (better than 67% compared with alternatives), overall professional sentiment and financial characteristics for the stock Dexcom are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Dexcom. The consolidated Growth Rank has a good rank of 68, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 68% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 94, which means that professional investors are more optimistic about the stock than for 94% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 10, which means that the share price of Dexcom is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 90% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 43, which means that the company has a financing structure that is riskier than those of 57% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
NASDAQ 100
NASDAQ
S&P 500
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
10 9 4 5
Growth
68 65 87 45
Safety
Safety
43 39 29 29
Sentiment
94 82 89 100
360° View
360° View
67 42 67 32
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
95 95 95 79
Opinions Change
86 52 63 67
Pro Holdings
n/a 88 98 94
Market Pulse
41 37 47 67
Sentiment
94 82 89 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
10 9 4 5
Growth
68 65 87 45
Safety Safety
43 39 29 29
Combined
23 19 27 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
32 14 10 20
Price vs. Earnings (P/E)
19 17 5 6
Price vs. Book (P/B)
15 20 12 14
Dividend Yield
1 1 1 1
Value
10 9 4 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
71 73 75 67
Profit Growth
70 76 94 34
Capital Growth
41 51 34 9
Stock Returns
62 27 67 91
Growth
68 65 87 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
27 20 22 25
Refinancing
16 14 17 25
Liquidity
87 97 90 67
Safety Safety
43 39 29 29

Similar Stocks

Discover high‑ranked alternatives to Dexcom and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.